Boston Scientific Jumps On Positive Surprise On Farapulse For AFIB Ablation

Signal(s) to enter, add, reduce, exit, hold or change.

News

Boston Scientific BSX stock is jumping 6.25% to $53.92 as of this writing on a positive surprise from ADVENT study. Farapulse Pulsed Field Ablation is a system in which electric fields selectively ablate heart tissue in patients with atrial fibrillation. The study shows that the system is not inferior to radiofrequency or cryoablation that are now standard-of-care.

Approval

In The Arora Report Analysis, the system is likely to be approved by next year.

Model Portfolio

BSX is in the core Model Portfolio.

Aging Population

The population is aging. Afib is more common in older patients. The prevalence of other heart diseases is also more common in older patients. Boston Scientific also makes pacemakers and defibrillators. The company also makes stents.

Boston Scientific is a beneficiary of the aging population.  

Zones

For those who are following the Good Way, the Buy Now rating is 🔒. To see the locked content, please click here to start a free trial.

For those following the Best Way, the buy zone is 🔒.

To learn about the Good Way and the Best Way, read the Getting a Running Start Guide.

The recommended quantity is 30% - 50%.

The very long term target remains $102 - $110.

What To Do Now

Those in the stock may consider continuing to hold. Those not in the stock may consider following the parameters given above.

The Arora Report is known for its accurate calls. The Arora Report correctly called the 2008 financial crash, the start of a mega bull market in 2009, the COVID crash, the post-COVID bull market, and the 2022 bear market.  Please click here to sign up for a free forever Generate Wealth Newsletter.